Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care

BACKGROUND: CYP2C19*2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse outcomes is discussed. We investigated the prognostic value of carriage of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothenbacher, Dietrich, Hoffmann, Michael M, Breitling, Lutz P, Rajman, Iris, Koenig, Wolfgang, Brenner, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765693/
https://www.ncbi.nlm.nih.gov/pubmed/23981380
http://dx.doi.org/10.1186/1471-2261-13-61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765693/
https://www.ncbi.nlm.nih.gov/pubmed/23981380
http://dx.doi.org/10.1186/1471-2261-13-61

Ejemplares similares